The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
273
Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
Hemoglobin A1C (A1C) at Week 18
A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent. The study hypothesis comparison was between sitagliptin versus placebo.
Time frame: Baseline and 18 Weeks
Fasting Plasma Glucose (FPG) at Week 18
The change from baseline is the Week 18 FPG minus the Week 0 FPG.
Time frame: Baseline and 18 Weeks
2-hour Post-meal Glucose (PMG) at Week 18
The change from baseline is the Week 18 PMG minus the Week 0 PMG.
Time frame: Baseline and 18 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.